An Expanded Phase I Study of Pazopanib and Everolimus in Patients With Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer

Trial Profile

An Expanded Phase I Study of Pazopanib and Everolimus in Patients With Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Everolimus (Primary) ; Pazopanib (Primary)
  • Indications Renal cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Aug 2017 Planned End Date changed from 1 Jun 2017 to 1 Aug 2017.
    • 10 Jun 2017 Biomarkers information updated
    • 11 Oct 2016 Results of efficacy and toxicity study in genomically profiled metastatic urogenital cancer patients, presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top